A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

NCT ID: NCT04680026

Last Updated: 2025-12-02

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-01
• Study Completion Date: 2025-12-31

Brief Summary

This Phase 2 study is a two-stage, serial cohort dose escalation and expansion study of a single 30-minute (IV) infusion of HBI-3000 for the conversion of patients with recent-onset atrial fibrillation (AF).

Stage A is open label and all patients will receive HBI-3000. In each of three dose cohorts, up to 10 patients will receive HBI-3000 by IV infusion (30 minutes). Three different dose levels are planned to be administered serially, lowest to highest, with assessment of safety, tolerability, and efficacy prior to proceeding to the next dose level group.

Following Stage A, the iDMC will recommend up to two doses of HBI-3000 to be further explored in Stage B. Stage B is a serial, randomized, double-blind and placebo-controlled cohort of two different doses of HBI-3000, with a dose decision after the first cohort. Stage B will be powered to show a difference between HBI-3000 and placebo in conversion rate at each of the two dose levels.

Detailed Description

This is a two-stage study in patients with AF of recent onset:

Stage A is open label and all patients will receive HBI-3000. In each of three dose cohorts, up to 10 patients will receive HBI-3000 by IV infusion (30 minutes). For each dosing cohort, sentinel dosing is planned. Each patient may enroll only once in the study, will be enrolled into only one dose cohort and receive only a single dose treatment. In Stage A, three different dose levels are planned to be administered serially, lowest to highest, with assessment of safety, tolerability, and efficacy prior to proceeding to the next dose level group. The actual dose levels may be modified, and additional dose levels may be considered based on the observed results at each cohort.

Stage B is the randomized, double-blind and placebo-controlled part of the study. Study drug for Stage B patients is either HBI-3000 or placebo. Two cohorts will be enrolled sequentially, lowest dose level first, with safety, efficacy, and available PK results evaluated by the Sponsor and iDMC prior to enrolling patients in the next/higher dose cohort. The dose level for the second cohort may be adjusted following interim review of results in the first cohort. Patients will be randomized to receive a single IV infusion of HBI 3000 or placebo over 30 minutes. In each of the dose cohorts, sequentially enrolled patients will be randomized at 2:1 ratio so that 40 patients will receive HBI 3000 infusion and 20 patients will receive placebo infusion. Each patient may enroll only once in the study, will be enrolled into only one dose cohort and receive only a single dose treatment.

Conditions

Atrial Fibrillation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Drug: HBI-3000, Stage A Dose Level 1

Stage A Open Label HBI-3000 Dose Level 1: 200 mg

Group Type: EXPERIMENTAL

HBI-3000

Intervention Type: DRUG

Small molecule, multi-ion channel blocker

Drug: HBI-3000, Stage A Dose Level 2

Stage A Open Label HBI-3000 Dose Level 2: 350 mg planned

Group Type: EXPERIMENTAL

HBI-3000

Intervention Type: DRUG

Small molecule, multi-ion channel blocker

Drug: HBI-3000, Stage A Dose Level 3

Stage A Open Label HBI-3000 Dose Level 2: 500 mg planned

Group Type: EXPERIMENTAL

HBI-3000

Intervention Type: DRUG

Small molecule, multi-ion channel blocker

Drug: HBI-3000, Stage B Dose Level 1

Stage B Double-blind placebo controlled, Cohort 1 HBI-3000 Dose Level 1: Selected based on Stage A results

Group Type: EXPERIMENTAL

HBI-3000

Intervention Type: DRUG

Small molecule, multi-ion channel blocker

Placebo

Intervention Type: DRUG

Normal saline

Drug: HBI-3000, Stage B Dose Level 2

Stage B Double-blind placebo controlled, Cohort 2 HBI-3000 Dose Level 2: Selected based on Stage A, and Stage B Cohort 1 results

Group Type: EXPERIMENTAL

HBI-3000

Intervention Type: DRUG

Small molecule, multi-ion channel blocker

Placebo

Intervention Type: DRUG

Normal saline

Interventions

HBI-3000

Small molecule, multi-ion channel blocker

Intervention Type: DRUG

Placebo

Normal saline

Intervention Type: DRUG

Other Intervention Names

sulcardine sulfate

Eligibility Criteria

Inclusion Criteria

• 18 to 80 years of age
• Sustained AF of > 2 hours and < 72 hours duration
• Eligible for cardioversion (electrical and pharmacologic)
• On adequate anticoagulant therapy or eligible for anticoagulation during treatment and for at least 30 days duration after treatment if indicated by ACC/AHA/HRS or country specific national or international guidelines for thromboembolic risk reduction related to AF

Exclusion Criteria

• Atrial fibrillation < 2 hours or > 72 hours duration or with duration not reliably established at the time of dosing
• Hemodynamic instability that may require emergency electrical cardioversion
• Atrial flutter
• Moderate to severe HF
• Clinical or ECG signs of acute cardiac ischemia or digitalis toxicity
• Known or suspected hyperthyroidism
• Cardiac surgery, stroke, TIA, acute MI/ PCI, unstable angina, or persistent angina at rest within the previous 3 months
• Presence of LA thrombus by TEE or TTE
• Presence of concurrent myocarditis or endocarditis
• ECG abnormalities: Current QTcF > 480 msec; QRS interval > 120 msec and/or a complete bundle branch block (BBB)l Delta wave or other pre-excitation pattern consistent with WPW syndrome; Acute coronary ischemia patterns
• Use of medication that prolongs the QTc interval or history of: Long QT syndrome, congenital or acquired; Torsades de Pointes (TdP); Brugada Syndrome; Ventricular arrhythmia (not including infrequent isolated PVC)
• Concurrent treatment with Class I or III antiarrhythmic drugs, metformin or strong CYP2D6 inhibitors (unless the medication is discontinued > 5 half-lives before enrollment)
• Treatment with oral amiodarone in the previous 3 months or IV amiodarone administered within 24 hours prior to planned Study Drug administration
• Use of vernakalant, or any experimental drug within 30 days or five half-lives (whichever is longer) of Study Drug administration, or use of an invasive investigational medical device within 2 months prior to Study Drug administration, or current enrollment in another study with investigational agent or procedure
• Clinically significant laboratory abnormalities

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

HUYABIO International, LLC.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

NCH Research Institute

Naples, Florida, United States

Prairie Education & Research

Springfield, Illinois, United States

North Mississippi Medical Center

Tupelo, Mississippi, United States

CHRISTUS Trinity Mother Frances Hospital - Tyler

Tyler, Texas, United States

University Clinical Center of the Republic of Srpska

Banja Luka, , Bosnia and Herzegovina

Montreal Heart Institute

Montreal, Quebec, Canada

Centre hospitalier de L'Universite de Montral (CHUM)

Montreal, Quebec, Canada

Centre integre de sante et de services sociaux de Lanaudiere - Hopital Pierre-Le Gardeur

Terrebonne, Quebec, Canada

Waikato Hospital

Hamilton, , New Zealand

Wellington Regional Hospital

Wellington, , New Zealand

Niš University Clinical Center

Niš, Bulevar Doktora, Serbia

University Clinical Center of Serbia

Belgrade, , Serbia

Dedinje Institute for Cardiovascular Diseases

Belgrade, , Serbia

University Hospital Medical Center Bezanijska kosa

Belgrade, , Serbia

Countries

United States; Bosnia and Herzegovina; Canada; New Zealand; Serbia

Other Identifiers

HBI-3000-402

Identifier Type: -

Identifier Source: org_study_id